Search results for "Other"

showing 10 items of 12132 documents

Non-cognate bystander cytolysis by clonal epitope-specific CTL lines through CD28-CD80 interaction inhibits antibody production: A potential caveat t…

2015

Abstract Adoptive transfer of virus epitope-specific CD8 T cells is an immunotherapy option to control cytomegalovirus (CMV) infection and prevent CMV organ disease in immunocompromised solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) recipients. The therapy aims at an early, selective recognition and cytolysis of infected cells for preventing viral spread in tissues with no adverse immunopathogenic side-effects by attack of uninfected bystander cells. Here we describe that virus epitope-specific, cloned T-cell lines lyse target cells that present the cognate antigenic peptide to the TCR, but simultaneously have the potential to lyse uninfected cells expressing…

0301 basic medicineCytotoxicity ImmunologicAdoptive cell transfermedicine.medical_treatmentImmunologyCytomegalovirusEpitopes T-Lymphocytechemical and pharmacologic phenomenaBiologyImmunotherapy AdoptiveEpitope03 medical and health sciencesMiceCD28 AntigensmedicineCytotoxic T cellAnimalsB-LymphocytesHematopoietic Stem Cell TransplantationCD28hemic and immune systemsImmunotherapyBystander EffectOrgan TransplantationVirologyClone CellsTransplantationCytolysis030104 developmental biologyAntibody FormationCytomegalovirus InfectionsB7-1 AntigenCD80T-Lymphocytes CytotoxicCellular immunology
researchProduct

Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.

2018

Transcutaneous immunization (TCI) is a novel vaccination strategy that utilizes skin-associated lymphatic tissue to induce immune responses. Employing T-cell epitopes and the TLR7 agonist imiquimod onto intact skin mounts strong primary, but limited memory CTL responses. To overcome this limitation, we developed a novel imiquimod-containing vaccination platform (IMI-Sol) rendering superior primary CD8+ and CD4+ T-cell responses. However, it has been unclear whether IMI-Sol per se is restricted in terms of memory formation and tumor protection. In our present work, we demonstrate that the combined administration of IMI-Sol and CD40 ligation unleashes fullblown specific T-cell responses in th…

0301 basic medicineCytotoxicity ImmunologicGraft RejectionSkin NeoplasmsOvalbuminmedicine.medical_treatmentT cellImmunologyCD40 Ligand610 MedizinMelanoma ExperimentalPriming (immunology)Gene ExpressionAdministration Cutaneous03 medical and health sciencesMice0302 clinical medicineImmune system610 Medical sciencesmedicineImmunology and AllergyCytotoxic T cellAnimalsSkinCD40ImiquimodMembrane GlycoproteinsbiologyT-Lymphocytes Helper-InducerAllograftsMice Inbred C57BLCTL*030104 developmental biologymedicine.anatomical_structureToll-Like Receptor 7biology.proteinCancer researchImmunizationImmunotherapyAdjuvantImmunologic MemoryCD8030215 immunologyCD27 LigandT-Lymphocytes CytotoxicEuropean journal of immunologyReferences
researchProduct

Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures.

2019

An emerging cellular immunotherapy for cancer is based on the cytolytic activity of natural killer (NK) cells against a wide range of tumors. Although in vitro activation, or "priming," of NK cells by exposure to pro-inflammatory cytokines, such as interleukin (IL)-2, has been extensively studied, the biological consequences of NK cell activation in response to target cell interactions have not been thoroughly characterized. We investigated the consequences of co-incubation with K562, CTV-1, Daudi RPMI-8226, and MCF-7 tumor cell lines on the phenotype, cytokine expression profile, and transcriptome of human NK cells. We observe the downregulation of several activation receptors including CD…

0301 basic medicineCytotoxicity ImmunologicPhysiologymedicine.medical_treatmentCytotoxicityGene ExpressionNK cellsLymphocyte ActivationToxicologyPathology and Laboratory MedicineMolecular biology assays and analysis techniquesChemokine receptor0302 clinical medicineNeoplasmsImmune PhysiologyCellular typesGene Regulatory NetworksIL-2 receptorReceptorInnate Immune SystemMultidisciplinaryNucleic acid analysisQImmune cellsRRNA analysisKiller Cells NaturalCytokinePhenotype030220 oncology & carcinogenesisMCF-7 CellsMedicineCytokinesWhite blood cellsTumor necrosis factor alphaImmunotherapyInflammation MediatorsResearch ArticleCell signalingCell biologyBlood cellsScienceImmunologyCD16BiologyResearch and Analysis Methods03 medical and health sciencesExtraction techniquesCell Line TumormedicineGeneticsHumansMolecular Biology TechniquesMolecular BiologySecretionMedicine and health sciencesBiology and life sciencesMolecular DevelopmentNKG2DRNA extraction030104 developmental biologyAnimal cellsImmune SystemCancer researchK562 CellsTranscriptomePhysiological ProcessesDevelopmental BiologyCloningPloS one
researchProduct

Modification of DNA structure by reactive nitrogen species as a result of 2-methoxyestradiol–induced neuronal nitric oxide synthase uncoupling in met…

2020

Abstract 2-methoxyestradiol (2-ME) is a physiological anticancer compound, metabolite of 17β-estradiol. Previously, our group evidenced that from mechanistic point of view one of anticancer mechanisms of action of 2-ME is specific induction and nuclear hijacking of neuronal nitric oxide synthase (nNOS), resulting in local generation of nitro-oxidative stress and finally, cancer cell death. The current study aims to establish the substantial mechanism of generation of reactive nitrogen species by 2-ME. We further achieved to identify the specific reactive nitrogen species involved in DNA-damaging mechanism of 2-ME. The study was performed using metastatic osteosarcoma 143B cells. We detected…

0301 basic medicineDNA damageClinical BiochemistryBone NeoplasmsNitric Oxide Synthase Type INitric OxideBiochemistryNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePeroxynitrous AcidHumansMTT assayViability assaylcsh:QH301-705.5Reactive nitrogen speciesSettore CHIM/02 - Chimica FisicaOsteosarcomalcsh:R5-920Settore BIO/16 - Anatomia UmanaOrganic ChemistryDNAReactive Nitrogen Species2-MethoxyestradiolPeroxynitrous acid030104 developmental biologychemistrylcsh:Biology (General)Settore CHIM/03 - Chimica Generale E InorganicaCancer cellBiophysicslcsh:Medicine (General)030217 neurology & neurosurgeryPeroxynitrite2 methoxyestradiol nitric oxide chemotherapyResearch PaperRedox Biology
researchProduct

Molecular surveillance of norovirus, 2005–16 : an epidemiological analysis of data collected from the NoroNet network

2018

BACKGROUND: The development of a vaccine for norovirus requires a detailed understanding of global genetic diversity of noroviruses. We analysed their epidemiology and diversity using surveillance data from the NoroNet network.METHODS: We included genetic sequences of norovirus specimens obtained from outbreak investigations and sporadic gastroenteritis cases between 2005 and 2016 in Europe, Asia, Oceania, and Africa. We genotyped norovirus sequences and analysed sequences that overlapped at open reading frame (ORF) 1 and ORF2. Additionally, we assessed the sampling date and country of origin of the first reported sequence to assess when and where novel drift variants originated.FINDINGS: W…

0301 basic medicineDatabases FactualvirusesVARIANTSmedicine.disease_causeDisease OutbreaksEMERGENCEfluids and secretions[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesEpidemiologyGenotypeTOOLmedia_commonCaliciviridae InfectionsMolecular Epidemiologyvirus diseasesrespiratory system3. Good healthGastroenteritis[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInfectious DiseasesGeography[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyRNA Viral[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyOUTBREAKSmedicine.medical_specialtyEUROPEGenotypeTRANSMISSIONVIRUSES[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/Virology03 medical and health sciencesSDG 3 - Good Health and Well-beingGenetic driftEnvironmental healthmedicinemedia_common.cataloged_instanceHumansEuropean unionRetrospective StudiesGenetic diversityMolecular epidemiologyNorovirusOutbreakGenetic Variation[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyADULTSdigestive system diseasesEVOLUTION030104 developmental biology3121 General medicine internal medicine and other clinical medicineNorovirushuman activities
researchProduct

Traits and risk factors of post-disaster infectious disease outbreaks: a systematic review.

2021

AbstractInfectious disease outbreaks are increasingly recognised as events that exacerbate impacts or prolong recovery following disasters. Yet, our understanding of the frequency, geography, characteristics and risk factors of post-disaster disease outbreaks globally is lacking. This limits the extent to which disease outbreak risks can be prepared for, monitored and responded to following disasters. Here, we conducted a global systematic review of post-disaster outbreaks and found that outbreaks linked to conflicts and hydrological events were most frequently reported, and most often caused by bacterial and water-borne agents. Lack of adequate WASH facilities and poor housing were commonl…

0301 basic medicineDisaster risk reductionScienceDiseaseCommunicable DiseasesArticleDisease OutbreaksDisasters03 medical and health sciences0302 clinical medicineEnvironmental healthMedicineHumans030212 general & internal medicineClimate-change mitigationScience & TechnologyMultidisciplinarybusiness.industryQRNatural hazardsOutbreakMultidisciplinary Sciences030104 developmental biologyVDP::Medisinske Fag: 700::Helsefag: 800Risk factorsInfectious disease (medical specialty)MedicineScience & Technology - Other TopicsInfectious diseasesEpidemiological ModelsbusinessClimate-change impactsPost disaster
researchProduct

The emergence of drug resistance to targeted cancer therapies: Clinical evidence.

2019

For many decades classical anti-tumor therapies included chemotherapy, radiation and surgery; however, in the last two decades, following the identification of the genomic drivers and main hallmarks of cancer, the introduction of therapies that target specific tumor-promoting oncogenic or non-oncogenic pathways, has revolutionized cancer therapeutics. Despite the significant progress in cancer therapy, clinical oncologists are often facing the primary impediment of anticancer drug resistance, as many cancer patients display either intrinsic chemoresistance from the very beginning of the therapy or after initial responses and upon repeated drug treatment cycles, acquired drug resistance deve…

0301 basic medicineDrugCancer Researchmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectTranslational researchApoptosisDrug resistanceMonoclonal antibodyBioinformatics03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansPharmacology (medical)Hedgehog ProteinsEpigeneticsProtein Kinase Inhibitorsmedia_commonPharmacologyChemotherapybusiness.industryCancerImmunotherapyProtein-Tyrosine Kinasesmedicine.disease030104 developmental biologyInfectious DiseasesOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisbusinessProteasome InhibitorsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

Cancer combination therapies with artemisinin-type drugs

2017

Artemisia annua L. is a Chinese medicinal plant, which is used throughout Asia and Africa as tea or press juice to treat malaria. The bioactivity of its chemical constituent, artemisinin is, however, much broader. We and others found that artemisinin and its derivatives also exert profound activity against tumor cells in vitro and in vivo. Should artemisinin-type drugs be applied routinely in clinical oncology in the future, then it should probably be as part of combination therapy regimens rather than as monotherapy. In the present review, I give a comprehensive overview on synergistic and additive effects of artemisinin-type drugs in combination with different types of cytotoxic agents an…

0301 basic medicineDrugCombination therapymedicine.medical_treatmentmedia_common.quotation_subjectArtemisia annuaDrug resistancePharmacologyBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoCell Line TumorNeoplasmsAntineoplastic Combined Chemotherapy Protocolsparasitic diseasesmedicineAnimalsHumansDrug InteractionsArtemisininmedia_commonPharmacologyBiological ProductsChemotherapyNatural productbiologybusiness.industryDrug SynergismDrugs Investigationalbiology.organism_classificationAntineoplastic Agents PhytogenicCombined Modality TherapyArtemisininsDrug Resistance Multiple030104 developmental biologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisChemical and Drug Induced Liver InjurybusinessSesquiterpenesmedicine.drugBiochemical Pharmacology
researchProduct

Mothering under the influence: How perinatal drugs of abuse alter the mother-infant interaction

2018

AbstractAlthough drug-abusing women try to moderate their drug and alcohol use during pregnancy, they often relapse at a time when childcare needs are high and maternal bonding is critical to an infant’s development. In the clinical setting, the search for the neural basis of drug-induced caregiving deficits is complex due to several intervening variables. Rather, the preclinical studies that control for drug dose and regimen, as well as for gestational and postpartum environment, allow a precise determination of the effects of drugs on maternal behaviour. Given the relevance of the issue, this review will gather reports on the phenotypic correlates of maternal behaviour in preclinical stud…

0301 basic medicineDrugMalecannabiSubstance-Related Disordersmedia_common.quotation_subjectMother infantcocainePrenatal Exposure Delayed EffectMaternal behaviourNicotine03 medical and health sciences0302 clinical medicinePregnancymedicineHumansMaternal Behaviormedia_commonPregnancymaternal behaviourbiologybusiness.industryalcoholGeneral Neurosciencestimulantperinatal substance usemedicine.diseasebiology.organism_classificationSubstance-Related DisorderMother-Child RelationsopiateRegimen030104 developmental biologyPrenatal Exposure Delayed EffectsSettore BIO/14 - FarmacologiaGestationFemaleCannabisbusiness030217 neurology & neurosurgeryClinical psychologymedicine.drugnicotineHuman
researchProduct

Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study

2019

<b><i>Objective:</i></b> Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should change the therapeutic aims, triggering a reduction in the number of drugs.<b><i></i></b>The main aim of this study is to describe the preventive and symptomatic drug treatments prescribed to patients discharged with a limited life expectancy from internal medicine and geriatric wards. The secondary aim was to describe the potentially severe drug-drug interactions (DDI). <b><i>Materials and Methods:</i></b> We analyzed Registry of Polytherapies Societa Italiana di Medicina I…

0301 basic medicineDrugMalemedicine.medical_specialtyDeprescriptions020205 medical informaticsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medications; Aged 80 and over; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Male; Polypharmacy; Deprescriptions; Life Expectancy; Patient DischargeSocio-culturale02 engineering and technology03 medical and health sciencesElderly · End of life · Limited life expectancy · Polypharmacy · Symptomatic medicationsPharmacotherapyDeprescriptionsLife ExpectancyElderlySymptomatic medications0202 electrical engineering electronic engineering information engineeringmedicine80 and overHumansLS4_4Medical prescriptionElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medicationsmedia_commonAgedPolypharmacyAged 80 and overOriginal Paperbusiness.industryGeneral MedicineElderly End-of-life Limited life expectancy Polypharmacy Preventing medications Symptomatic medicationsElderly End of life Limited life expectancy Polypharmacy Symptomatic medicationsPatient DischargeClonidineLimited life expectancyItalyEmergency medicineEnd of lifeLife expectancyPolypharmacyFemale030101 anatomy & morphologyDeprescribingbusinessmedicine.drugSymptomatic medication
researchProduct